Latest Attention-deficit hyperactivity disorder management Stories
FLORHAM PARK, N.J., May 9, 2011 /PRNewswire/ -- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the publication in Pediatrics of data demonstrating the efficacy of non-stimulant KAPVAY(TM) (clonidine hydrochloride) extended-release tablets when combined with stimulant medications for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents (6-17 years).
A subgroup of adults with attention-deficit hyperactivity disorder (ADHD) also exhibit excessive emotional reactions to everyday occurrences, and this combination of ADHD and emotional reactivity appears to run in families.
WARREN, N.J., April 25, 2011 /PRNewswire/ -- MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilmÂ® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease. Under terms of the agreement, the companies will...
Humans are not born as blank slates for nature to write on. Neither are they behaving on genes alone.
According to a new study from Sweden, the earlier babies are born, the more likely they are to later get a prescription for ADHD medication.
A new study in the March 1 issue of the journal SLEEP indicates that the ability of children with attention deficit hyperactivity disorder to remain vigilant and attentive deteriorated significantly after losing less than one hour of nightly sleep for a week.
Faced with the risk of developing side effects, even ones as mild as fatigue, nausea and fuzzy thinking, many older patients are willing to forego medications that provide only average benefit in preventing heart attack.
PHILADELPHIA, February 28, 2011 /PRNewswire-FirstCall/ -- Shire plc, (http://www.shire.com/shireplc/en/home ) (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the use of once-daily INTUNIV(R) (guanfacine) Extended-Release Tablets (http://www.intuniv.com/) as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents ages 6 to...
Measurements of hand movement control may help determine the severity of attention deficit hyperactivity disorder (ADHD) in children.
- Small missiles, especially grape, canister, fragments of iron, and the like, when fired, as upon an enemy at close quarters.
- To fire mitraille at.